New Local Pharmaceutical Plant Expected To Enhance Access To Drugs In Kenya 12/01/2018 Justus Wanzala Kenya’s pharmaceutical products manufacturing sector is hopeful it will experience significant growth after the Square Pharmaceuticals ltd (SPL) of Bangladesh commissioned a US$ 75 million plant in the East African nation this week. [A reminder: this story, like all of our stories, is completely free for almost every developing country in the world. Just sign up for a free password here!] Continue reading -> A Canadian Billionaire’s Mysterious Death And The Effect On Access To Medicines 20/12/2017 William New The mysterious death last week of Canadian billionaire Barry Sherman and his wife has raised many questions. For some, one question is what impact it will have on pharmaceutical competition in Canada, as his giant generic medicines company Apotex was seen as making a mark in access to medicines. It was also recalled that the company is the only one to have used an obscure provision of a World Trade Organization intellectual property agreement aimed at making more affordable medicines available in least developed countries. Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
A Canadian Billionaire’s Mysterious Death And The Effect On Access To Medicines 20/12/2017 William New The mysterious death last week of Canadian billionaire Barry Sherman and his wife has raised many questions. For some, one question is what impact it will have on pharmaceutical competition in Canada, as his giant generic medicines company Apotex was seen as making a mark in access to medicines. It was also recalled that the company is the only one to have used an obscure provision of a World Trade Organization intellectual property agreement aimed at making more affordable medicines available in least developed countries. Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> Posts navigation Older postsNewer posts